Follow‐up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: impact on allogeneic haematopoietic stem cell transplantation

Abstract

1551–1560. Nijhof, I.S., Groen, R.W., Noort, W.A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J.J., Parren, P.W., Lokhorst, H.M., van de Donk, N.W., Martens, A.C. & Mutis, T. (2015) Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clinical Cancer Research, 21, 2802–2810. Nimmerjahn, F. & Ravetch, J.V. (2008) Fcgamma receptors as regulators of immune responses. Nature Reviews Immunology, 8, 34–47. Usmani, S.Z., Weiss, B.M., Plesner, T., Bahlis, N.J., Belch, A., Lonial, S., Lokhorst, H.M., Voorhees, P.M., Richardson, P.G., Chari, A., Sasser, A.K., Axel, A., Feng, H., Uhlar, C.M., Wang, J., Khan, I., Ahmadi, T. & Nahi, H. (2016) Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood, 128, 37–44.